OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
OS Therapies (NYSE-A: OSTX) has announced the formation of a new subsidiary, OS Drug Conjugates (OSDC), alongside strategic initiatives to leverage its patented silicone dioxide-based, pH-sensitive tunable antibody drug conjugates (tADC) and drug conjugates (tDC) platforms. The company is pursuing discussions with clinical-stage ADC therapeutics companies across the U.S. and China to establish joint ventures, with plans to spin these JVs into standalone public companies.
The company's proprietary technology utilizes SiLinkers™, pH-sensitive silicon-based linkers that connect targeting antibodies with therapeutic agents. This system is designed to release therapeutic agents specifically within tumors and their microenvironment, where pH levels are lower, maximizing treatment effectiveness while reducing harm to healthy cells.
According to BCC Research, the global antibody-drug conjugates market is projected to grow from $10.8 billion in 2023 to $47.0 billion by 2029, representing a CAGR of 28.4%.
OS Therapies (NYSE-A: OSTX) ha annunciato la creazione di una nuova sussidiaria, OS Drug Conjugates (OSDC), insieme a iniziative strategiche per sfruttare le sue piattaforme brevettate di coniugati di farmaci basati su silice, sensibili al pH, e coniugati di farmaci (tDC). L'azienda sta intraprendendo discussioni con aziende di terapie ADC in fase clinica negli Stati Uniti e in Cina per stabilire joint venture, con l'intento di trasformare queste JV in aziende pubbliche indipendenti.
La tecnologia proprietaria dell'azienda utilizza SiLinkers™, connettori a base di silicio sensibili al pH che collegano anticorpi di targeting con agenti terapeutici. Questo sistema è progettato per rilasciare agenti terapeutici specificamente all'interno dei tumori e del loro microambiente, dove i livelli di pH sono più bassi, massimizzando l'efficacia del trattamento riducendo al contempo il danno alle cellule sane.
Secondo BCC Research, il mercato globale dei coniugati anticorpo-farmaco è previsto crescere da $10,8 miliardi nel 2023 a $47,0 miliardi entro il 2029, rappresentando un CAGR del 28,4%.
OS Therapies (NYSE-A: OSTX) ha anunciado la formación de una nueva subsidiaria, OS Drug Conjugates (OSDC), junto con iniciativas estratégicas para aprovechar sus plataformas patentadas de conjugados de fármacos basados en dióxido de silicio, sensibles al pH, y conjugados de fármacos (tDC). La empresa está llevando a cabo discusiones con empresas de terapias ADC en etapa clínica en EE. UU. y China para establecer empresas conjuntas, con planes de convertir estas JV en compañías públicas independientes.
La tecnología propietaria de la empresa utiliza SiLinkers™, conectores a base de silicio sensibles al pH que conectan anticuerpos dirigidos con agentes terapéuticos. Este sistema está diseñado para liberar agentes terapéuticos específicamente dentro de los tumores y su microentorno, donde los niveles de pH son más bajos, maximizando la efectividad del tratamiento mientras se reduce el daño a las células sanas.
Según BCC Research, se proyecta que el mercado global de conjugados anticuerpo-fármaco crecerá de $10.8 mil millones en 2023 a $47.0 mil millones para 2029, lo que representa una tasa compuesta anual (CAGR) del 28.4%.
OS Therapies (NYSE-A: OSTX)는 새로운 자회사 OS Drug Conjugates (OSDC)의 설립을 발표했으며, 특허받은 실리카 기반의 pH 민감 조절 가능한 항체 약물 접합체(tADC) 및 약물 접합체(tDC) 플랫폼을 활용하기 위한 전략적 이니셔티브를 추진하고 있습니다. 이 회사는 미국과 중국의 임상 단계 ADC 치료제 회사들과 공동 투자 설립을 위한 논의를 진행 중이며, 이러한 JV를 독립적인 상장 회사로 전환할 계획입니다.
회사의 독점 기술은 SiLinkers™를 활용하며, 이는 표적 항체와 치료제를 연결하는 pH 민감 실리콘 기반의 링커입니다. 이 시스템은 pH 수준이 낮은 종양과 그 미세 환경 내에서 치료제를 특이적으로 방출하도록 설계되어, 치료 효과를 극대화하고 건강한 세포에 대한 피해를 줄입니다.
BCC Research에 따르면, 전 세계 항체-약물 접합체 시장은 2023년 108억 달러에서 2029년 470억 달러로 성장할 것으로 예상되며, 이는 연평균 성장률(CAGR) 28.4%에 해당합니다.
OS Therapies (NYSE-A: OSTX) a annoncé la création d'une nouvelle filiale, OS Drug Conjugates (OSDC), accompagnée d'initiatives stratégiques pour tirer parti de ses plateformes brevetées de conjugués de médicaments à base de dioxyde de silicium, sensibles au pH, ainsi que de conjugués de médicaments (tDC). L'entreprise mène des discussions avec des sociétés de thérapies ADC en phase clinique aux États-Unis et en Chine pour établir des coentreprises, avec des projets de transformer ces JV en entreprises publiques autonomes.
La technologie propriétaire de l'entreprise utilise des SiLinkers™, des connecteurs à base de silicium sensibles au pH qui relient des anticorps ciblés à des agents thérapeutiques. Ce système est conçu pour libérer des agents thérapeutiques spécifiquement dans les tumeurs et leur microenvironnement, où les niveaux de pH sont plus bas, maximisant ainsi l'efficacité du traitement tout en réduisant les dommages aux cellules saines.
Selon BCC Research, le marché mondial des conjugués anticorps-médicaments devrait passer de 10,8 milliards de dollars en 2023 à 47,0 milliards de dollars d'ici 2029, représentant un TCAC de 28,4 %.
OS Therapies (NYSE-A: OSTX) hat die Gründung einer neuen Tochtergesellschaft, OS Drug Conjugates (OSDC), bekannt gegeben, zusammen mit strategischen Initiativen zur Nutzung seiner patentierten, pH-sensitiven, einstellbaren Antikörper-Arzneimittel-Konjugate (tADC) und Arzneimittel-Konjugate (tDC) Plattformen. Das Unternehmen führt Gespräche mit klinisch tätigen ADC-Therapieunternehmen in den USA und China, um Joint Ventures zu gründen, mit dem Ziel, diese JVs in eigenständige öffentliche Unternehmen umzuwandeln.
Die proprietäre Technologie des Unternehmens nutzt SiLinkers™, pH-sensitive, silikonbasierte Verbindungsstücke, die zielgerichtete Antikörper mit therapeutischen Wirkstoffen verbinden. Dieses System ist darauf ausgelegt, therapeutische Wirkstoffe speziell innerhalb von Tumoren und deren Mikroumgebung freizusetzen, wo die pH-Werte niedriger sind, um die Behandlungseffektivität zu maximieren und gleichzeitig Schäden an gesunden Zellen zu reduzieren.
Laut BCC Research wird erwartet, dass der globale Markt für Antikörper-Arzneimittel-Konjugate von 10,8 Milliarden US-Dollar im Jahr 2023 auf 47,0 Milliarden US-Dollar bis 2029 wachsen wird, was einem CAGR von 28,4% entspricht.
- Strategic formation of OS Drug Conjugates subsidiary to unlock value from proprietary technology
- Potential creation of shareholder value through stock dividends from planned public JV spinoffs
- Company's technology operates in a rapidly growing market projected to reach $47.0 billion by 2029
- Innovative pH-sensitive technology potentially offering improved therapeutic targeting
- None.
Insights
The formation of OS Drug Conjugates (OSDC) represents a strategic pivot to capitalize on OS Therapies' innovative tunable Antibody Drug Conjugate (tADC) technology. Their proprietary SiLinkers™ platform offers two distinct technical advantages: pH-sensitive drug release and multi-drug payload capability. This approach could potentially overcome two major limitations of current ADCs - non-specific toxicity and single-drug resistance.
The strategic decision to pursue joint ventures rather than independent development signals a capital-efficient approach to value creation. By partnering with clinical-stage ADC companies, particularly in the U.S. and China, OSTX could accelerate market entry while sharing development risks. The planned structure of spinning off JVs into public companies, with stock dividends to shareholders, provides a mechanism for value capture without diluting the parent company.
The timing aligns with explosive growth in the ADC market, projected to reach
The pH-sensitive silicon-based technology could be particularly attractive to potential partners as it addresses a fundamental challenge in ADC development - the therapeutic window between efficacy and toxicity. The ability to selectively release drugs in the acidic tumor microenvironment while sparing healthy tissues could provide a significant competitive advantage in a crowded ADC landscape.
The OST-tADC and OST-tDC technologies are centered around the Company's proprietary next-generation tunable Antibody Drug Conjugate (tADC) and tunable Drug Conjugates (tDC) platforms. These advanced technologies incorporate pH-sensitive silicon-based linkers: SiLinkers™ to link the targeting antibodies (or antibody fragments) and therapeutic moieties together while coating the entire package with pH sensitive coating. This strategy can release multiple therapeutic agents selectively within the tumor and tumor microenvironment, which have lower pH levels than the rest of the body. This approach aims to maximize the therapeutic effects while minimizing damage to healthy cells.
BCC Research estimates that the global market for antibody-drug conjugates is estimated to increase from
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received rare pediatric disease, fast-track and orphan drug designations from the USFDA. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, with positive results released in the first quarter of 2025. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224482242/en/
OS Therapies Contact Information:
Jack Doll
571.243.9455
Irpr@ostherapies.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
Source: OS Therapies, Inc.
FAQ
What is the market potential for OS Therapies' (OSTX) ADC technology through 2029?
How will OSTX shareholders benefit from the new OS Drug Conjugates subsidiary?
What is unique about OS Therapies' (OSTX) SiLinkers technology?
Which regions is OSTX targeting for joint venture partnerships?
